摘要:
Ribavirin derivatives represented by the formula (II), pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula (II) for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula (II) are disclosed.
摘要:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
摘要:
The present invention discloses novel compounds of Formula I which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
摘要:
A compound represented by formula (I), wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R1 is a straight or branched chain (C4 to C5) alkyl group substituted by one or two amino acid ester grou ps convertible in vivo into a hydroxy group or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
摘要:
An antifungal compound represented by formula (I), wherein X is independently both F or both Cl or one X is F and the other is Cl; Y = (a), (b), (c), (d), (e), (f) or (g); R' = (C1-C10)alkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, (C3-C8)cycloalkyl or CH2R?2; R2 = (C¿1-C3)perhaloalkyl, CO2R3, *CH(OR4)CH2OR4 or CH¿2?N(R?5); R3¿ = lower alkyl or H; R4 = R3 or (CH¿2?)2OR?3; R5¿ = lower alkyl; Z = H or (C¿1?-C5)alkanoyl and the carbons with the asterisks (*) have the R or S absolute configuration; or a pharmaceutically acceptable salt thereof as well as pharmaceutical compositions containing them and a method of treating or preventing fungal infections in mammals using them are disclosed.
摘要:
A compound represented by formula (I) wherein X is independently both F or both Cl or one X is independently F and the other is independently Cl; R1 is a straight or branched chain (C3 to C8) alkyl group substituted by one or two hydroxy moieties, an ether or ester (e.g., a polyestherester or phosphate ester) thereof a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
摘要:
A method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin derivative of formula (I) and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
摘要:
Novel tricyclic N-cyanoimine compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl-protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic N-cyanoimines compound to a biological system. In particular, the method inhibits the abnormal growth of cells in mammals such as a human.
摘要:
A compound represented by a formula selected from the group consisting of (Ia) and (Ib), wherein X is independently selected from the group consisting of F and Cl; A is CH or N; R1 is a straight or branched chain (C3 to C8) alkyl group substituted by one or two hydroxy moieties, an ether or ester thereof (e.g., a polyether ester, a heterocyclic ester, an amino acid ester or phosphate ester thereof) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions thereof useful for treating and/or preventing fungal infections are disclosed.
摘要:
The present invention discloses novel compounds of Formula I which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.